NCT03198026 - Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

September 11, 2026

Study Completion Date

February 20, 2032

Conditions

Non-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Nodal Marginal Zone LymphomaAnn Abor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Nodal Marginal Zone LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Nodal Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent Non-hodgkin LymphomaStage II Splenic Marginal Zone LymphomaStage III Splenic Marginal Zone LymphomaStage IV Splenic Marginal Zone Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia